HUTCHMED (China) Limited ( (HK:0013) ) has shared an announcement.
HUTCHMED (China) Limited announced that its New Drug Application for TAZVERIK® (tazemetostat) has received conditional approval from the National Medical Products Administration (NMPA) in China for treating adult patients with relapsed or refractory follicular lymphoma with EZH2 mutation. This marks the first approval of an EZH2 inhibitor in China and represents HUTCHMED’s first foray into hematological malignancies, highlighting the company’s commitment to addressing unmet medical needs and expanding its footprint in this disease area. The approval is based on a multicenter Phase II bridging study in China and clinical studies by Epizyme, Inc. outside China, demonstrating promising efficacy and safety. The strategic partnership with Epizyme allows HUTCHMED to handle research, development, manufacturing, and commercialization of TAZVERIK® in China, while Epizyme retains marketing authorization.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought several drug candidates from in-house discovery to market, with its first three medicines available in China and one approved globally, including in the US, Europe, and Japan.
YTD Price Performance: 4.26%
Average Trading Volume: 42,963
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £2.01B
For an in-depth examination of 0013 stock, go to TipRanks’ Stock Analysis page.